Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration.
The study included healthy adult men, aged 25-45, who ingested one of three butyrate forms, with blood samples and ...
Announcing a new publication for Acta Materia Medica journal. The UPLC-QqQ-MS/MS method was established, validated, and used ...
1 Department of Pharmacy, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China 2 Department of Pharmacy, Nanjing Drum Tower Hospital Clinical ...